Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival

Steffen Marquardt; Martha M. Kirstein; Roland Brüning; Martin Zeile; Pier Francesco Ferrucci; Warner Prevoo; Boris Radeleff; Hervé Trillaud; Lambros Tselikas; Emilio Vicente; Philipp Wiggermann; Michael P. Manns; Arndt Vogel; Frank K. Wacker

doi:10.1007/s00330-018-5729-z

Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival

Steffen Marquardt, Martha M. Kirstein, Roland Brüning, Martin Zeile, Pier Francesco Ferrucci, Warner Prevoo, Boris Radeleff, Hervé Trillaud, Lambros Tselikas, Emilio Vicente, Philipp Wiggermann, Michael P. Manns, Arndt Vogel, Frank K. Wacker^*

^*Korrespondierende/r Autor/-in für diese Arbeit

Medizinische Klinik I

38 Zitate (Scopus)

Abstract

Objectives: Cholangiocarcinoma is the second most common primary liver tumour with a poor overall prognosis. Percutaneous hepatic perfusion (PHP) is a directed therapy for primary and secondary liver malignancies, and its efficacy and safety have been shown in different entities. The purpose of this study was to prove the safety and efficacy of PHP in patients with unresectable intrahepatic cholangiocarcinoma (iCCA). Patients and methods: We retrospectively reviewed data from 15 patients with unresectable iCCA treated with PHP in nine different hospitals throughout Europe. Overall response rates (ORR) were assessed according to response evaluation criteria in solid tumours (RECIST1.1). Overall survival (OS), progression-free survival (PFS) and hepatic PFS (hPFS) were analysed using the Kaplan-Meier estimation. Adverse events (AEs) and toxicity were evaluated. Results: Fifteen patients were treated with 26 PHPs. ORR was 20%, disease control was achieved in 53% after the first PHP. Median OS was 26.9 months from initial diagnosis and 7.6 months from first PHP. Median PFS and hPFS were 122 and 131 days, respectively. Patients with liver-only disease had a significantly longer median OS compared to patients with locoregional lymph node metastases (12.9 vs. 4.8 months, respectively; p < 0.01). Haematological toxicity was common, but manageable. No AEs of grade 3 or 4 occurred during the procedures. Discussion: PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with iCCA, especially in non-metastatic disease. Key Points: • Percutaneous hepatic perfusion (PHP) offers an additional locoregional therapy strategy for the treatment of unresectable primary or secondary intrahepatic malignancies. • PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with intrahepatic cholangiocarcinoma (iCCA), especially in non-metastatic disease. • Side effects seem to be tolerable and comparable to other systemic or local treatment strategies.

Originalsprache	Englisch
Zeitschrift	European Radiology
Jahrgang	29
Ausgabenummer	4
Seiten (von - bis)	1882-1892
Seitenumfang	11
ISSN	0938-7994
DOIs	https://doi.org/10.1007/s00330-018-5729-z
Publikationsstatus	Veröffentlicht - 01.04.2019

Fördermittel

Conflict of interest Steffen Marquardt reports a travel grant and lecture fees from Delcath Systems, Inc. during the conduct of the study. Martha M. Kirstein has no conflicts of interest related to the subject matter of the article. She received honoraria and travel grants from Shire, Novartis, Ipsen and Roche outside the submitted work. Roland Brüning has no conflicts of interest related to the subject matter of the article or outside the submitted work. Martin Zeile reports consulting and proctoring fees from Delcath systems, Inc. He reports consulting fees for Boston Scientific, Inc. outside the submitted work. Pier Francesco Ferrucci has no conflicts of interest related to the subject matter of the article or outside the submitted work. Warner Prevoo reports proctoring fees from Delcath systems, Inc. Boris Radeleff has no conflicts of interest related to the subject matter of the article or outside the submitted work. Hervé Trillaud has no conflicts of interest related to the subject matter of the article or outside the submitted work. Lambros Tselikas has no conflicts of interest related to the subject matter of the article. He reports proctoring/speaking fees for Cook Medical, BTG, GE Healthcare, Sirtex Medical, AMGEN and Pfizer. Emilio Vicente has no conflicts of interest related to the subject matter of the article or outside the submitted work. Philipp Wiggermann takes part in "FOCUS Trial in Hepatic Dominant Ocular Melanoma - A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma". He has no conflicts of interest outside the submitted work. Michael P. Manns has no conflicts of interest related to the subject matter of the article or outside the submitted work. Arndt Vogel reports personal fees and travel grants from Delcath Systems, Inc. He reports personal fees from Roche, Bayer, Lilly, Incyte, BMS, MSD and Amgen outside the submitted work. Frank K. Wacker reports a grant and personal/proctoring fees from Delcath Systems, Inc. during the conduct of the study. He reports grants from Siemens Healthineers, Promedicus Ltd., BMBF, Forschungscampus STIMULATE, DFG, Rebirth-Cluster of Excellence and personal fees from Novartis Pharma GmbH outside the submitted work. After data collection of the current study, Hannover Medical School participated in the Phase 2 Clinical Trials in Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC) (NCT 02415036).

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Dokumente

10.1007/s00330-018-5729-z

Weitere Links

Link to publication in Scopus

Fingerprint

Untersuchen Sie die Forschungsthemen von „Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren

Marquardt, S., Kirstein, M. M., Brüning, R., Zeile, M., Ferrucci, P. F., Prevoo, W., Radeleff, B., Trillaud, H., Tselikas, L., Vicente, E., Wiggermann, P., Manns, M. P., Vogel, A., & Wacker, F. K. (2019). Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. European Radiology, 29(4), 1882-1892. https://doi.org/10.1007/s00330-018-5729-z

@article{2a7c121d6bc547eca977a34b461ab768,

title = "Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival",

abstract = "Objectives: Cholangiocarcinoma is the second most common primary liver tumour with a poor overall prognosis. Percutaneous hepatic perfusion (PHP) is a directed therapy for primary and secondary liver malignancies, and its efficacy and safety have been shown in different entities. The purpose of this study was to prove the safety and efficacy of PHP in patients with unresectable intrahepatic cholangiocarcinoma (iCCA). Patients and methods: We retrospectively reviewed data from 15 patients with unresectable iCCA treated with PHP in nine different hospitals throughout Europe. Overall response rates (ORR) were assessed according to response evaluation criteria in solid tumours (RECIST1.1). Overall survival (OS), progression-free survival (PFS) and hepatic PFS (hPFS) were analysed using the Kaplan-Meier estimation. Adverse events (AEs) and toxicity were evaluated. Results: Fifteen patients were treated with 26 PHPs. ORR was 20\%, disease control was achieved in 53\% after the first PHP. Median OS was 26.9 months from initial diagnosis and 7.6 months from first PHP. Median PFS and hPFS were 122 and 131 days, respectively. Patients with liver-only disease had a significantly longer median OS compared to patients with locoregional lymph node metastases (12.9 vs. 4.8 months, respectively; p < 0.01). Haematological toxicity was common, but manageable. No AEs of grade 3 or 4 occurred during the procedures. Discussion: PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with iCCA, especially in non-metastatic disease. Key Points: • Percutaneous hepatic perfusion (PHP) offers an additional locoregional therapy strategy for the treatment of unresectable primary or secondary intrahepatic malignancies. • PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with intrahepatic cholangiocarcinoma (iCCA), especially in non-metastatic disease. • Side effects seem to be tolerable and comparable to other systemic or local treatment strategies.",

author = "Steffen Marquardt and Kirstein, \{Martha M.\} and Roland Br{\"u}ning and Martin Zeile and Ferrucci, \{Pier Francesco\} and Warner Prevoo and Boris Radeleff and Herv{\'e} Trillaud and Lambros Tselikas and Emilio Vicente and Philipp Wiggermann and Manns, \{Michael P.\} and Arndt Vogel and Wacker, \{Frank K.\}",

note = "Publisher Copyright: {\textcopyright} 2018, European Society of Radiology.",

year = "2019",

month = apr,

day = "1",

doi = "10.1007/s00330-018-5729-z",

language = "English",

volume = "29",

pages = "1882--1892",

journal = "European Radiology",

issn = "0938-7994",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "4",

}

Marquardt, S, Kirstein, MM, Brüning, R, Zeile, M, Ferrucci, PF, Prevoo, W, Radeleff, B, Trillaud, H, Tselikas, L, Vicente, E, Wiggermann, P, Manns, MP, Vogel, A & Wacker, FK 2019, 'Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival', European Radiology, Jg. 29, Nr. 4, S. 1882-1892. https://doi.org/10.1007/s00330-018-5729-z

Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. / Marquardt, Steffen; Kirstein, Martha M.; Brüning, Roland et al.
in: European Radiology, Jahrgang 29, Nr. 4, 01.04.2019, S. 1882-1892.

Publikation: Beiträge in Fachzeitschriften › Zeitschriftenaufsätze › Forschung › Begutachtung

TY - JOUR

T1 - Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival

AU - Marquardt, Steffen

AU - Kirstein, Martha M.

AU - Brüning, Roland

AU - Zeile, Martin

AU - Ferrucci, Pier Francesco

AU - Prevoo, Warner

AU - Radeleff, Boris

AU - Trillaud, Hervé

AU - Tselikas, Lambros

AU - Vicente, Emilio

AU - Wiggermann, Philipp

AU - Manns, Michael P.

AU - Vogel, Arndt

AU - Wacker, Frank K.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Objectives: Cholangiocarcinoma is the second most common primary liver tumour with a poor overall prognosis. Percutaneous hepatic perfusion (PHP) is a directed therapy for primary and secondary liver malignancies, and its efficacy and safety have been shown in different entities. The purpose of this study was to prove the safety and efficacy of PHP in patients with unresectable intrahepatic cholangiocarcinoma (iCCA). Patients and methods: We retrospectively reviewed data from 15 patients with unresectable iCCA treated with PHP in nine different hospitals throughout Europe. Overall response rates (ORR) were assessed according to response evaluation criteria in solid tumours (RECIST1.1). Overall survival (OS), progression-free survival (PFS) and hepatic PFS (hPFS) were analysed using the Kaplan-Meier estimation. Adverse events (AEs) and toxicity were evaluated. Results: Fifteen patients were treated with 26 PHPs. ORR was 20%, disease control was achieved in 53% after the first PHP. Median OS was 26.9 months from initial diagnosis and 7.6 months from first PHP. Median PFS and hPFS were 122 and 131 days, respectively. Patients with liver-only disease had a significantly longer median OS compared to patients with locoregional lymph node metastases (12.9 vs. 4.8 months, respectively; p < 0.01). Haematological toxicity was common, but manageable. No AEs of grade 3 or 4 occurred during the procedures. Discussion: PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with iCCA, especially in non-metastatic disease. Key Points: • Percutaneous hepatic perfusion (PHP) offers an additional locoregional therapy strategy for the treatment of unresectable primary or secondary intrahepatic malignancies. • PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with intrahepatic cholangiocarcinoma (iCCA), especially in non-metastatic disease. • Side effects seem to be tolerable and comparable to other systemic or local treatment strategies.

AB - Objectives: Cholangiocarcinoma is the second most common primary liver tumour with a poor overall prognosis. Percutaneous hepatic perfusion (PHP) is a directed therapy for primary and secondary liver malignancies, and its efficacy and safety have been shown in different entities. The purpose of this study was to prove the safety and efficacy of PHP in patients with unresectable intrahepatic cholangiocarcinoma (iCCA). Patients and methods: We retrospectively reviewed data from 15 patients with unresectable iCCA treated with PHP in nine different hospitals throughout Europe. Overall response rates (ORR) were assessed according to response evaluation criteria in solid tumours (RECIST1.1). Overall survival (OS), progression-free survival (PFS) and hepatic PFS (hPFS) were analysed using the Kaplan-Meier estimation. Adverse events (AEs) and toxicity were evaluated. Results: Fifteen patients were treated with 26 PHPs. ORR was 20%, disease control was achieved in 53% after the first PHP. Median OS was 26.9 months from initial diagnosis and 7.6 months from first PHP. Median PFS and hPFS were 122 and 131 days, respectively. Patients with liver-only disease had a significantly longer median OS compared to patients with locoregional lymph node metastases (12.9 vs. 4.8 months, respectively; p < 0.01). Haematological toxicity was common, but manageable. No AEs of grade 3 or 4 occurred during the procedures. Discussion: PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with iCCA, especially in non-metastatic disease. Key Points: • Percutaneous hepatic perfusion (PHP) offers an additional locoregional therapy strategy for the treatment of unresectable primary or secondary intrahepatic malignancies. • PHP is a standardised and safe procedure that provides promising response rates and survival data in patients with intrahepatic cholangiocarcinoma (iCCA), especially in non-metastatic disease. • Side effects seem to be tolerable and comparable to other systemic or local treatment strategies.

UR - https://www.scopus.com/pages/publications/85053938614

U2 - 10.1007/s00330-018-5729-z

DO - 10.1007/s00330-018-5729-z

M3 - Journal articles

C2 - 30255257

AN - SCOPUS:85053938614

SN - 0938-7994

VL - 29

SP - 1882

EP - 1892

JO - European Radiology

JF - European Radiology

IS - 4

ER -